Cyrano Therapeutics

Cyrano Therapeutics Secures $9M for Development of Treatment for Post-Viral Smell Loss

Cyrano Therapeutics Secures $9.0 Million Series B Financing to Advance Clinical Development of CYR-064 for Treatment of Post-Viral Smell Loss. Phase 2 FLAVOR clinical trial currently enrolling 150 patients to assess the safety and effectiveness of CYR-064 in treating patients with chronic smell loss following recovery from a viral infection (post-viral hyposmia) No FDA-approved drug […]

Cyrano Therapeutics Enrolls First Patient in Phase 2 Trial of CYR-064 for Post-Viral Smell Loss (Hyposmia)

There is currently no FDA-approved therapy for this increasingly prevalent and serious chronic sensory condition Delray Beach, FL, October 12, 2023 – Cyrano Therapeutics, Inc., a regenerative medicine company pioneering the development of treatments for smell loss, announced today that it has commenced enrollment in the Phase 2 FLAVOR trial,  a randomized, double-blinded, placebo-controlled, multi-dose clinical trial of […]